Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 813 participants.

Also called NCT01885208

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 813 participants (enrolled count) (from the registry)
Sponsor
  • Novo Nordisk Registry lists this organization as the lead sponsor
Registry
  • NCT NCT01885208
  • EudraCT 2012-004826-92
Other papers using this trial's data
  • Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial Diabetes care, 2018-02 DOI, PubMed 29246950
  • Impact on HbA1c and body weight of switching from other GLP-1 receptor agonists to semaglutide: A model-based approach Diabetes, obesity & metabolism, 2019-01 DOI, PubMed 30047216, PMC6585654 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide as a therapeutic option for elderly patients with type 2 diabetes: Pooled analysis of the SUSTAIN 1-5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29687620, PMC6099273 In the PMC Open Access subset under CC BY-NC.
  • Semaglutide induces weight loss in subjects with type 2 diabetes regardless of baseline BMI or gastrointestinal adverse events in the SUSTAIN 1 to 5 trials Diabetes, obesity & metabolism, 2018-09 DOI, PubMed 29766634, PMC6099440 In the PMC Open Access subset under CC BY-NC.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Croatia, Finland, France, Germany, Greece, Italy, Netherlands, Puerto Rico, Serbia, Switzerland, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01885208. Randomized; no masking; primary purpose treatment. Start 2013-12-02 (actual); primary completion 2015-07-13 (actual). Results posted on 2018-03-30.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes
Acronym
SUSTAIN™ 3
Condition
Diabetes
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
semaglutide
Intervention (Drug)
exenatide
Lead sponsor
Novo Nordisk A/S (class: industry)

Record details

Record id
cardio:ct-nct01885208
Content hash
a35bed87ea06ffa09dcef73ee04147a6a28b89cadffd77872cb948ba7ea9d47d